Insmed Reports Strong Second-Quarter 2026 Financial Results and Raises BRINSUPRI Revenue Guidance

Details

BRINSUPRI revenues grew 49% sequentially to $309.2 million, and ARIKAYCE revenues grew 8% sequentially to $116.3 million. The company raised its full-year 2026 BRINSUPRI revenue guidance to a range of $1.25 billion to $1.40 billion and reiterated its ARIKAYCE revenue guidance of $450 million to $470 million. Insmed also provided updates on its clinical trials and regulatory submissions across its therapeutic areas. The company's net loss for the second quarter of 2026 was $13.2 million, or $0.06 per share, compared to a net loss of $321.7 million, or $1.70 per share, for the second quarter of 2025.

Items reported

About Insmed Inc.

Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.